The president offered a proclamation Saturday to begin duties on Canada, Mexico, and China. Musk says Tesla's robotaxis will hit Austin this summer. But after years of unfulfilled promises, investors ...
1d
uk.investing.com on MSNFutures higher, Amazon to report, earnings deluge - what's moving marketsInvesting.com - U.S. stock futures climb on Thursday as traders gauge a stream of corporate earnings and fresh U.S. economic data. Amazon (NASDAQ:AMZN) is set to report its quarterly results, with ...
US stocks were mixed on Thursday in anticipation of Amazon's quarterly results, as investors assessed the earnings season so ...
Investing.com--US stocks edged higher Thursday, as investors assessed a deluge of corporate earnings as well as more labor market data. At 09:45 ET (14:45 GMT), the Dow Jones Industrial Average rose ...
Don't swing for the fences even as the stock market scales worries, says Citi. Here's its barbell portfolio. Investors should take a more prudent approach during a volatile first half ...
21h
Barchart on MSNStocks See Support from Positive Earnings ResultsStocks today are seeing support from some positive earnings results. Tapestry is up more than +13% after reporting stronger-than-expected Q2 adjusted EPS and raising its full-year adjusted EPS ...
In a report released yesterday, Mark Lipacis from Evercore ISI maintained a Hold rating on Qualcomm (QCOM – Research Report), with a price ...
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
1h
Hosted on MSNWe Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug WarsShares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results